They were able to confirm a diagnosis of BL versus DLBCL in 82% of the cases using the first phase of studies (CD10, bcl2, and morphology) and in 92% of cases with the addition of testing for Ki-67, CD38, and CD44 [27]. This evidence concerns the gene BCL2 and Burkitt lymphoma.